SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
BOSTON, Dec. 11, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that it will host a conference call and webcast slide presentation on Wednesday, December 16, 2015 at 4:30 PM ET to provide a corporate update and discuss the Company's 2016 outlook.
The call can be accessed by dialing (877) 751-7350 (U.S. and Canada) or (918) 559-5237 (international). The passcode for the conference call is 6055343. To access the slide and live audio webcast, or the subsequent archived recording, visit the "Investors & Media" section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two (2) weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and more precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
CONTACT: Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
[email protected]
David Pitts
Argot Partners
212-600-1902
[email protected]
